Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

SHRINK????

Opioid pain med market in 2011 was $8 Billion when Pfizer paid $3.6 Billion for King to acquire Embeda. Today that market had almost doubled ~ $15 Billion and growing aT 3.8% CAGR AND is to be expected to exceed $25 Billion in 2021. DO THE MATH!

Now why is that? Since I wrote the following post before some joined the conversation, perhaps it is worth posting it again...

To begin with, there is a pain med migration from OTC drugs to prescribed drugs at a larger scale due to the aging boomers, who are not only a sizable group, but appear to be less tolerant of aging and, thus, wish to have access to pain meds that will alleviate or eliminate (an impossible task at times) all of their pain. Then there are the increasing numbers of surgical procedures on a global basis that are a source of acute pain and require pain medications; often opioids. Further, aging is as true in ASIA as the US, which means growth outside the US is likely to be greater; particularly if you consider the emerging markets are not only growing their income levels but with it expectations for better healthcare and pain management. It is also worth noting that the US generally accounts for about half of the opioid pain med market. Still, with a movement in Asia to an increase in middle class income status, and with it expectations of better healthcare, demand may well exceed the forecasted growth.